Eteplirsen in the treatment of Duchenne muscular dystrophy
By K. Lim, R. Maruyama, T. Yokota. Drug Design, Development and Therapy, 2017
692 citations recorded by the source corpus.
Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500–5,000 male births that is characterized by progressive muscular deterioration. It is inherited in an X-linked recessive fashion and is caused by loss-of-function mutations in the DMD gene coding for dystrophin, a cytoskeletal protein that stabilizes the plasma membrane of muscle fibers. In September 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin production by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants. Eteplirsen is applicable for approximately 14% of patients with DMD mutations. This article extensively reviews and discusses the available information on eteplirsen to date, focusing on pharmacological, efficacy, safety, and tolerability data from preclinical and clinical trials. Issues faced by eteplirsen, particularly those relating to its efficacy, will be identified. Finally, the place of eteplirsen and exon skipping as a general therapeutic strategy in Duchenne muscular dystrophy treatment will be discussed.
Subfields: Cell Biology, Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/f8c4348b72a05df5b6b27753b2f76f2eefe2eba2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cell Biology
In Genetics
In Molecular Biology
Citations in the corpus
- Chemistry, structure and function of approved oligonucleotide therapeutics (2023, background): “Considering that 5 out of the 16 oligonucleotide therapeutics approved to date are splice-shifting oligos (Figure 3) and that they have paved the road to treatments of devastating diseases for which there are no cures, certainly the development of SSOs should be seen as a success, despite the somewh”
- The delivery of therapeutic oligonucleotides (2016, background): “The 2013 approval of the first major antisense drug, Kynamro R © (2), an inhibitor of apolipoprotein B expression, was accompanied by promising clinical trials involving siRNA (3) and splice switching oligonucleotides (SSOs) (4).”